Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.57 per share a year ago.
Will Mirum Pharmaceuticals, Inc. (MIRM) Report Negative Q3 Earnings? What You Should Know
Mirum Pharmaceuticals (MIRM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mirum Pharmaceuticals (MIRM) Up 4.5% Since Last Earnings Report: Can It Continue?
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
Mirum (MIRM) Banks on Livmarli, Overdependence a Concern
Mirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The recent label expansion of the drug should drive sales further.
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2024 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q2 2024 Results Conference Call August 7, 2024 4:30 PM ET Company Participants Andrew McKibben - Vice President, Investor Relations Chris Peetz - Chief Executive Officer Peter Radovich - President & Chief Operating Officer Joanne Quan - Chief Medical Officer Eric Bjerkholt - Chief Financial Officer Conference Call Participants Jon Wolleben - Citizens JMP Steven Seedhouse - Raymond James David Lebowitz - Citi Mike Ulz - Morgan Stanley Jessica Fye - JPMorgan Gavin Clark-Gartner - Evercore ISI Mani Foroohar - Leerink Partners Dae Gon Ha - Stifel Operator Good afternoon, everyone, and welcome to the Mirum Pharmaceuticals reports Second Quarter 2024 Financial Results and provides Business Update. My name is Carla, and I will be coordinating your call today.
Mirum's (MIRM) Q2 Earnings Lag Estimates, Revenues Top
Mirum's (MIRM) earnings miss estimates in the second quarter of 2024 while revenues beat the same. Livmarli drives year-over-year sales.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.92 per share a year ago.
Mirum Pharmaceuticals (MIRM) Surges 7.3%: Is This an Indication of Further Gains?
Mirum Pharmaceuticals (MIRM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Bullish On Mirum Pharmaceuticals: Enhanced Portfolio With Strategic Acquisition
Mirum Pharmaceuticals develops therapies for rare liver diseases, focusing on bile acid regulation. Key products include Livmarli, Cholbam, and Chenodal, with Chenodal recently completing Phase 3 trials for CTX. MIRM's pipeline also has Volixibat in Phase 2b trials for PSC and PBC.
Mirum (MIRM) Gets EC Approval for Livmarli Label Expansion
The European Commission approves Mirum's (MIRM) Livmarli for the treatment of progressive familial intrahepatic cholestasis in patients three months of age and older.
Mirum (MIRM) Rises More Than 30% in Past 3 Months: Here's Why
The recent label expansion of Mirum's (MIRM) lead drug, Livmarli, is expected to drive sales in the upcoming quarters. The company's efforts to build its pipeline beyond Livmarli also hold promise.
Mirum (MIRM) Soars on Interim Data From Liver Disease Studies
Mirum (MIRM) posts positive interim data from two phase IIb studies evaluating volixibat in patients with primary biliary cholangitis and primary sclerosing cholangitis. Stock rises.
